These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26321630)

  • 1. TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy.
    Fiorillo AA; Heier CR; Novak JS; Tully CB; Brown KJ; Uaesoontrachoon K; Vila MC; Ngheim PP; Bello L; Kornegay JN; Angelini C; Partridge TA; Nagaraju K; Hoffman EP
    Cell Rep; 2015 Sep; 12(10):1678-90. PubMed ID: 26321630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
    Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
    Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
    Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
    Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy.
    Cacchiarelli D; Incitti T; Martone J; Cesana M; Cazzella V; Santini T; Sthandier O; Bozzoni I
    EMBO Rep; 2011 Feb; 12(2):136-41. PubMed ID: 21212803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
    Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
    Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
    Yokota T; Nakamura A; Nagata T; Saito T; Kobayashi M; Aoki Y; Echigoya Y; Partridge T; Hoffman EP; Takeda S
    Nucleic Acid Ther; 2012 Oct; 22(5):306-15. PubMed ID: 22888777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DMD transcript imbalance determines dystrophin levels.
    Spitali P; van den Bergen JC; Verhaart IE; Wokke B; Janson AA; van den Eijnde R; den Dunnen JT; Laros JF; Verschuuren JJ; 't Hoen PA; Aartsma-Rus A
    FASEB J; 2013 Dec; 27(12):4909-16. PubMed ID: 23975932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle.
    Martin PT; Golden B; Okerblom J; Camboni M; Chandrasekharan K; Xu R; Varki A; Flanigan KM; Kornegay JN
    PLoS One; 2014; 9(2):e88226. PubMed ID: 24505439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment.
    Assereto S; Stringara S; Sotgia F; Bonuccelli G; Broccolini A; Pedemonte M; Traverso M; Biancheri R; Zara F; Bruno C; Lisanti MP; Minetti C
    Am J Physiol Cell Physiol; 2006 Feb; 290(2):C577-82. PubMed ID: 16192300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.
    Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD
    PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.
    Veltrop M; van Vliet L; Hulsker M; Claassens J; Brouwers C; Breukel C; van der Kaa J; Linssen MM; den Dunnen JT; Verbeek S; Aartsma-Rus A; van Putten M
    PLoS One; 2018; 13(2):e0193289. PubMed ID: 29466448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
    Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
    PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.
    Alexander MS; Casar JC; Motohashi N; Vieira NM; Eisenberg I; Marshall JL; Gasperini MJ; Lek A; Myers JA; Estrella EA; Kang PB; Shapiro F; Rahimov F; Kawahara G; Widrick JJ; Kunkel LM
    J Clin Invest; 2014 Jun; 124(6):2651-67. PubMed ID: 24789910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition.
    Tanihata J; Nagata T; Ito N; Saito T; Nakamura A; Minamisawa S; Aoki Y; Ruegg UT; Takeda S
    Biochem Biophys Res Commun; 2018 Oct; 505(1):51-59. PubMed ID: 30236982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
    Maruyama R; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.
    Porter JD; Merriam AP; Leahy P; Gong B; Feuerman J; Cheng G; Khanna S
    Hum Mol Genet; 2004 Feb; 13(3):257-69. PubMed ID: 14681298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.